- Home
- EDD vs ABEO Comparison
EDD vs ABEO Comparison
Compare EDD & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDD
- ABEO
- Stock Information
- Founded
- EDD 2007
- ABEO 1974
- Country
- EDD United States
- ABEO United States
- Employees
- EDD N/A
- ABEO N/A
- Industry
- EDD Finance Companies
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- EDD Finance
- ABEO Health Care
- Exchange
- EDD Nasdaq
- ABEO Nasdaq
- Market Cap
- EDD 327.4M
- ABEO 304.4M
- IPO Year
- EDD N/A
- ABEO 1980
- Fundamental
- Price
- EDD $5.13
- ABEO $6.53
- Analyst Decision
- EDD
- ABEO Strong Buy
- Analyst Count
- EDD 0
- ABEO 6
- Target Price
- EDD N/A
- ABEO $18.00
- AVG Volume (30 Days)
- EDD 254.3K
- ABEO 1.1M
- Earning Date
- EDD 01-01-0001
- ABEO 08-11-2025
- Dividend Yield
- EDD 7.52%
- ABEO N/A
- EPS Growth
- EDD N/A
- ABEO N/A
- EPS
- EDD N/A
- ABEO N/A
- Revenue
- EDD N/A
- ABEO N/A
- Revenue This Year
- EDD N/A
- ABEO N/A
- Revenue Next Year
- EDD N/A
- ABEO $322.37
- P/E Ratio
- EDD N/A
- ABEO N/A
- Revenue Growth
- EDD N/A
- ABEO N/A
- 52 Week Low
- EDD $4.22
- ABEO $3.93
- 52 Week High
- EDD $4.95
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- EDD 52.61
- ABEO 58.79
- Support Level
- EDD $4.96
- ABEO $6.50
- Resistance Level
- EDD $5.21
- ABEO $6.84
- Average True Range (ATR)
- EDD 0.08
- ABEO 0.28
- MACD
- EDD -0.01
- ABEO 0.07
- Stochastic Oscillator
- EDD 56.67
- ABEO 59.59
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.